The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …
MLL-rearranged leukemias—an update on science and clinical approaches
AC Winters, KM Bernt - Frontiers in pediatrics, 2017 - frontiersin.org
The mixed-lineage leukemia 1 (MLL1) gene (now renamed Lysine [K]-specific
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-
family interactions makes it challenging to predict cell fate via standard molecular biology …
family interactions makes it challenging to predict cell fate via standard molecular biology …
Pathways and mechanisms of venetoclax resistance
P Bose, V Gandhi, M Konopleva - Leukemia & lymphoma, 2017 - Taylor & Francis
The approval of venetoclax, a 'BH3-mimetic'antagonist of the BCL-2 anti-apoptotic protein,
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …
Precision medicine in acute lymphoblastic leukemia
CH Pui - Frontiers of medicine, 2020 - Springer
The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …
Targeting BCL-2 in cancer: advances, challenges, and perspectives
Simple Summary Apoptosis, a programmed form of cell death, represents the main
mechanism by which cells die. Such phenomenon is highly regulated by the BCL-2 family of …
mechanism by which cells die. Such phenomenon is highly regulated by the BCL-2 family of …
DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
L Godfrey, NT Crump, R Thorne, IJ Lau… - Nature …, 2019 - nature.com
Enhancer elements are a key regulatory feature of many important genes. Several general
features including the presence of specific histone modifications are used to demarcate …
features including the presence of specific histone modifications are used to demarcate …
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities
TH Tran, SP Hunger - Seminars in cancer biology, 2022 - Elsevier
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and constitutes
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
The clinical success of the BCL-2-selective BH3-mimetic venetoclax in patients with poor
prognosis chronic lymphocytic leukemia (CLL) highlights the potential of targeting the BCL-2 …
prognosis chronic lymphocytic leukemia (CLL) highlights the potential of targeting the BCL-2 …
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal
prognosis. Survival outcomes have remained static in recent decades despite treatment …
prognosis. Survival outcomes have remained static in recent decades despite treatment …